Fig. 3: Kaplan–Meier survival curves depicting the overall survival of ALK-positive patients who received Lorlatinib with and without brain metastasis and those received one vs two or more TKI. | BJC Reports

Fig. 3: Kaplan–Meier survival curves depicting the overall survival of ALK-positive patients who received Lorlatinib with and without brain metastasis and those received one vs two or more TKI.

From: Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings

Fig. 3

a The median OS in patients with brain metastasis was 36 months (95% CI 23.4–41.5), which was statistically similar to patients without brain metastasis with a median OS of 16 months (95% CI 11.0–30.1) (p = 0.09). b The median OS of patients receiving more than one TKI and those receiving one TKI was 16 months vs NR (p = 0.03).

Back to article page